Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
Carsten Utoft Niemann,Caspar da Cunha-Bang,Marie Helleberg,Sisse R. Ostrowski,Christian Brieghel +4 more
TLDR
Patients with CLL with close hospital contactss and in particular those above 70 years of age with one or more comorbidities should be considered for closer monitoring and pre-emptive antiviral therapy upon a positive SARS-CoV-2 test.About:
This article is published in Blood.The article was published on 2022-05-19 and is currently open access. It has received 32 citations till now. The article focuses on the topics: Medicine & Medicine.read more
Citations
More filters
Journal ArticleDOI
COVID-19 in patients with hematologic malignancy
Petra Langerbeins,Michael Hallek +1 more
TL;DR: In this article , the authors showed that the immune response to SARS-CoV-2 vaccines may be significantly impaired, as only half of patients with hematologic malignancy develop a measurable anti-viral antibody response.
Journal ArticleDOI
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Livio Pagano,Jon Salmanton-García,Francesco Marchesi,Ola Blennow,Maria Gomes da Silva,Andreas Glenthøj,Jaap van Doesum,Yavuz M. Bilgin,Alberto Lopez-Garcia,F. Itri,R. Nunes Rodrigues,Barbora Weinbergerova,Francesca Farina,Giulia Dragonetti,Caroline Berg Venemyr,Jens Van Praet,Ozren Jakšić,Toni Valković,Iker Falces-Romero,Sonia Martín Pérez,Moraima Jiménez,J. Dávila-Valls,Martin Schonlein,Emanuele Ammatuna,Stef Meers,Mario Delia,Zlate Stojanoski,Anna Nordlander,Tobias Lahmer,László Imre Pinczés,Caterina Buquicchio,Klára Piukovics,Irati Ormazabal-Vélez,Nicola Stefano Fracchiolla,Michail Samarkos,Gustavo-Adolfo Méndez,Jose Angel Hernandez-Rivas,Ildefonso Espigado,Martin Cernan,Verena Petzer,Sylvain Lamure,Roberta Di Blasi,J. Marques de Almeida,Michelina Dargenio,Monika Biernat,Mariarita Sciumè,Cristina de Ramón,N. D. de Jonge,Josip Batinic,Avinash Aujayeb,Monia Marchetti,Guillemette Fouquet,Noemi Fernandez Escalada,Giovanni Zambrotta,M. Sacchi,Anna Guidetti,Fatih Demirken,Lucia Prezioso,Zdenek Racil,Marcio Nucci,Miloš Mladenović,Raphael Liévin,Michaela Hanakova,S. Grafe,Uluhan Sili,Marina Machado,Chiara Cattaneo,Tatjana Adzic-Vukicevic,Luisa Verga,Jorge Labrador,Laman Rahimli,Matteo Bonanni,Francesco Passamonti,Antonio Pagliuca,Paolo Corradini,Martin Hoenigl,Philipp Koehler,Alessandro Busca,Oliver A. Cornely +78 more
TL;DR: While mortality is significantly lower than in the pre-vaccination era, breakthrough COVID-19 in HM is still associated with considerable mortality.
Journal ArticleDOI
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
Ola Blennow,Jon Salmanton-García,Piotr Nowak,F. Itri,Jaap van Doesum,Alberto Lopez-Garcia,Francesca Farina,Ozren Jakšić,László Imre Princzés,Yavuz M. Bilgin,Iker Falces-Romero,Moraima Jiménez,Irati Ormazabal-Vélez,Barbora Weinbergerova,Remy Dulery,Zlate Stojanoski,Tobias Lahmer,Noemí Fernández,Jose Angel Hernandez-Rivas,Verena Petzer,N. D. de Jonge,Andreas Glenthøj,Cristina de Ramón,Monika Biernat,Nicola Stefano Fracchiolla,Avinash Aujayeb,Jens Van Praet,Martin Schönlein,Gustavo-Adolfo Méndez,Chiara Cattaneo,Anna Guidetti,Mariarita Sciumè,Emanuele Ammatuna,Raul Cordoba,Nicole Garcia-Pouton,Stefanie Katharina Gräfe,Alba Cabirta,Dominik Wolf,Anna Nordlander,Ramón García-Sanz,Mario Delia,Caroline Berg Venemyr,C Brones,Roberta Di Blasi,Elizabeth de Kort,Stef Meers,Sylvain Lamure,L. Serrano,Maria Merelli,Nicola Coppola,Rui Bergantim,Caroline Besson,Milena Kohn,Jessica Petiti,Carolina Garcia-Vidal,Michelina Dargenio,François Danion,Marina Machado,Rebeca Bailén-Almorox,Martin Hoenigl,Giulia Dragonetti,Louis Yi Ann Chai,Chi Shan Bonnie Kho,Matteo Bonanni,Raphael Liévin,Francesco Marchesi,Oliver A. Cornely,Livio Pagano +67 more
TL;DR: Risk factors, antiviral treatment and outcomes of SARS-CoV-2 omicron variant infection in 593 HM patients included in the EPICOVIDEHA registry are described.
Journal ArticleDOI
SARS-CoV-2 in immunocompromised individuals
Susan DeWolf,Justin Laracy,Miguel-Angel Perales,Mini Kamboj,Marcel R.M. van den Brink,Santosh Vardhana +5 more
TL;DR: Melms et al. as discussed by the authors presented what is known about distinct states of immunologic vulnerability to SARS-CoV-2 and how this information can be harnessed to improve prevention and treatment strategies for immunologically high-risk populations.
Journal ArticleDOI
Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era
Jérémie Zerbit,Marion Detroit,Antoine Meyer,Justine Decroocq,Bénédicte Deau-Fischer,P. Deschamps,Rudy Birsen,Johanna Mondesir,Patricia Franchi,Elsa Miekoutima,Corinne Guerin,Rui Batista,Didier Bouscary,Lise Willems,Marguerite Vignon +14 more
TL;DR: In this paper , the authors conducted a prospective observational study to identify the specific risks of the outpatient population with hematological diseases, and found that patients with malignancies are at greater risk of severe COVID-19 infection.
References
More filters
Journal ArticleDOI
Remdesivir for the Treatment of Covid-19 - Final Report.
John H. Beigel,Kay M. Tomashek,Lori E. Dodd,Aneesh K. Mehta,Barry S. Zingman,Andre C. Kalil,Elizabeth L. Hohmann,Helen Y. Chu,Annie Luetkemeyer,Susan Kline,Diego Lopez de Castilla,Robert W. Finberg,Kerry Dierberg,Victor F. Tapson,Lanny Hsieh,Thomas F. Patterson,Roger Paredes,Daniel A. Sweeney,William R. Short,Giota Touloumi,David Chien Lye,Norio Ohmagari,Myoung-don Oh,Guillermo M. Ruiz-Palacios,Thomas Benfield,Gerd Fätkenheuer,Mark G. Kortepeter,Robert L. Atmar,C. Buddy Creech,JD Lundgren,Abdel G. Babiker,Sarah Pett,James D. Neaton,Timothy Burgess,Tyler Bonnett,Michelle Green,Mat Makowski,Anu Osinusi,Seema U Nayak,H. Clifford Lane +39 more
TL;DR: The data show that remdesivir was superior to placebo in shortening the time to recovery in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
Journal ArticleDOI
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Sho Iketani,Lihong Liu,Yicheng Guo,Liyuan Liu,Jasper Fuk-Woo Chan,Yiming Huang,Maple Wang,Yang Luo,Jian Yu,Hin Chu,Kenn Ka-Heng Chik,Terrence Tsz-Tai Yuen,Michael T. Yin,Magdalena E. Sobieszczyk,Yaoxing Huang,Kwok-Yung Yuen,Harris H. Wang,Zizhang Sheng,David D. Ho +18 more
TL;DR: The identification of the Omicron (B.1.1) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 20211 immediately caused concern owing to the number of alterations in the spike glycoprotein that could lead to antibody evasion as discussed by the authors .
Journal ArticleDOI
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
Yair Herishanu,Irit Avivi,Anat Amit Aharon,Gabi Shefer,Shai Levi,Yotam Bronstein,Miguel Morales,Tomer Ziv,Yamit Shorer Arbel,Lydia Scarfò,Erel Joffe,Chava Perry,Paolo Ghia +12 more
TL;DR: In this article, the authors evaluated humoral immune responses to the BNT162b2 mRNA COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects.
Journal ArticleDOI
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients.
Abi Vijenthira,Inna Y. Gong,Thomas Andrew Fox,Stephen Booth,Gordon Cook,Bruno Fattizzo,Fernando Martín-Moro,Jerome Razanamahery,John Riches,Jeffrey I. Zwicker,Rushad Patell,Marie-Christiane Mb Vekemans,Lydia Scarfò,Thomas Chatzikonstantinou,Halil Yildiz,Raphaël Lattenist,Ioannis Mantzaris,William A. Wood,Lisa K. Hicks,Lisa K. Hicks +19 more
TL;DR: Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying and adults aged ≥60 years have significantly higher mortality; pediatric patients appear to be relatively spared.